Celgene raises FY18 adjusted EPS view to $8.70-$8.75 from about $8.45

Consensus is $8.52. Raises FY18 total revenue view to about $15B from about $14.8B, consensus $14.93B. Raises FY Revlimid net product sales view to about $9.7B from about $9.5B. Still sees Pomalyst/Imnovid net product sales about $2B, Otezla net product sales about $1.5B, Abraxane net product sales about $1B.

https://bit.ly/2Lo2dG2